• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

In Canada, More Mandatory Switching


In Canada, a new jurisdiction inaugurates mandatory switching to biosimilars.

The Northwest Territories has become the fifth Canadian jurisdiction to mandate switching to biosimilars for patients in the public health system. The Northwest Territories is a sparsely populated (41,000) wilderness area that is known for its native settlements, European immigration, fur trade and gold prospecting history (Yellowknife).

Public officials said in a statement that the biosimilar switching policy will be consistent with those already established in British Columbia, New Brunswick, Alberta, and Quebec. Canada has begun imposing mandatory biosimilar switching programs following lackluster voluntary biosimilar uptake. Biosimilars are highly similar to the original brand drugs they reference and just as safe and efficacious. They enter the market at discounts to the originator drugs and help to bring down the costs of health care and improve patient access to critical medicines.

The Canadian Rheumatology Association strongly recommends that access to citrate-free Humira be made available for Canadian children requiring treatment with Humira.

A statement by Biosimilars Canada, a trade association of biosimilars producers, explained that in the Northwest Territories switching will become mandatory for patients on 10 biologic reference drugs for which biosimilars are available, within the following therapeutic areas: arthritis, diabetes, inflammatory bowel disease, and psoriasis. The transition to biosimilars must occur by June 20, 2022.

“The full benefits of biosimilars cannot be realized unless drug plans adopt policies that support their expanded use with the implementation of successful biosimilar transitioning or “switching” policy,” the group said.

Related Videos
Lakesha Farmer from Cencora
Ha Kung Wong, JD.
Prerakkumar Parikh, PharmD
Chelsee Jensen, PharmD, BCPS
GBW 2023 webinar
Ryan Haumschild, PharmD, MS, MBA
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University,
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University,
Fran Gregory, PharmD, MBA
Julie Reed
Related Content
© 2024 MJH Life Sciences

All rights reserved.